Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
Neoadjuvant PD-1 blockade is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet immunological mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samples from a phase 2 clinical trial (NCT02259621), we explored whether the peripheral T cell clonotypic dynamics can serve as a biomarker for response to neoadjuvant PD-1 blockade. T cell receptor (TCR) sequencing was performed on serial peripheral blood, tumor and normal lung samples from resectable NSCLC patients treated with neoadjuvant PD-1 blockade. We explored the temporal dynamics of the T cell repertoire in the peripheral and tumoral compartments in response to neoadjuvant PD-1 blockade by using the TCR as a molecular barcode. Higher intratumoral TCR clonality was associated with reduced percent residual tumor at the time of surgery, and the TCR repertoire of tumors with major pathologic response (MPR; <10% residual tumor after neoadjuvant therapy) had a higher clonality and greater sharing of tumor infiltrating clonotypes with the peripheral blood relative to tumors without MPR. Additionally, the post-treatment tumor bed of patients with MPR was enriched with T cell clones that had peripherally expanded between weeks 2-4 after anti-PD-1 initiation and the intratumoral space occupied by these clonotypes was inversely correlated with percent residual tumor. Our study suggests that exchange of T cell clones between tumor and blood represents a key correlate of pathologic response to neoadjuvant immunotherapy, and shows that the periphery may be a previously underappreciated originating compartment for effective anti-tumor immunity.